Maynard Um
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) PT Lowered to $6 at BofA Securities
-
-
-
-
-
-
-
Biodexa initiates phase 3 trial for FAP treatment eRapa
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) PT Lowered to $8 at BofA Securities
-
-
-
-
-
-
-
Recursion's Altitude Lab startup has raised $154 million
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 1c
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) PT Lowered to $6 at Jefferies
-
-
-
-
-
-
-
After-hours movers: Micron Technology, Levi, AeroVironment, and more
-
466,314 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


